Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Inclusion Criteria:

- Subfoveal CNV due to presumed ocular histoplasmosis of less than 1 year duration

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age greater than or equal to 21 years of age

- CNV lesion of than < 5400 microns in diameter

- Best corrected visual acuity of 20/40-20/320

- Birth control therapy for females of child-bearing potential

Exclusion Criteria:

- Subfoveal NCV due tp presumed ocular histoplasmosis for > 1 year

- Pregnancy or lactation premenopausal women not using adequate contraception

- Prior enrollment in the study

- Any other condition that the Investigator believes would pose a significant hazard to
the subject

- Participation in another simultaneous medical investigation or trial

- Participation in another trial or previous trial of ranibizumab or Avastin

- Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that
could require medical or surgical intervention or ifa allowed to progress, could
likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the
12-month study period

- Previous panretinal photocoagulation

- Previous steroids or PDT in 3 months

- Previous participation in any studies of investigational drugs within 30 days
preceding Day 0

- Prior participation in a Genentech ranibizumab clinical trial

- Previous treatment with intravitreally (in either eye) or intravenously administered
Avastin within 3 months

- Previous use of Macugen in the study eye within 3 months

- Prior submacular surgery